Evidence map›Paper›PMID 33752752›Full record

Trial reportTrials2021

Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY): a multi-center randomized controlled study comparing alternative antibiotic regimens in patients undergoing tumor resections with endoprosthetic replacements-a statistical analysis plan.

Patricia Schneider, Diane Heels-Ansdell, Lehana Thabane, Michelle Ghert, PARITY Investigators

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01479283 (Prophylactic Antibiotic Regimens in Tumor Surgery), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01479283 phase3completednot on this map

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements

TypeinterventionalSponsorMcMaster UniversityRan2013 to 2021Enrolled602ConditionsInfection, Bone NeoplasmsArms24-Hour Prophylactic Cefazolin* Antibiotic Regimen, 5-Days Prophylactic Cefazolin* Antibiotic Regimen
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Patricia SchneiderDepartment of Surgery, McMaster University, Hamilton, ON, L8V 1C3, Canada.
Diane Heels-AnsdellDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, L8S 4L8, ON, Canada.
Lehana ThabaneDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, L8S 4L8, ON, Canada.
Michelle GhertDepartment of Surgery, McMaster University, Hamilton, ON, L8V 1C3, Canada. ghertm@mcmaster.ca.
PARITY Investigators
Impact · CAJuravinski Cancer Centre · CAJuravinski Hospital · CAMcMaster University · CA

Funding

Canadian Cancer Society Research Institute 701639Canadian Cancer Society Research Institute 703398Canadian Orthopaedic Foundation J. Édouard Samson Award 2018Institute of Cancer Research 157189Orthopaedic Research and Education Foundation Musculoskeletal Tumor Society (MSTS) Clinical Research GrantPhysicians' Services Incorporated Foundation N/A
6 · The paper itself

Abstract

backgroundLimb salvage with endoprosthetic reconstruction is the current standard practice for the surgical management of lower extremity bone tumors in skeletally mature patients and typically includes tumor resection followed by the functional limb reconstruction with modular metallic and polyethylene endoprosthetic implants. However, owing to the complexity and length of these procedures, as well as the immunocompromised nature of patients treated with chemotherapy, the risk of surgical site infection (SSI) is high. The primary research objective of the Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial is to assess whether a 5-day regimen of post-operative antibiotics decreases the risk of SSI at 1 year post-operatively compared to a 1-day regimen. This article describes the statistical analysis plan for the PARITY trial. METHODS/

designThe PARITY trial is an ongoing multi-center, blinded parallel two-arm randomized controlled trial (RCT) of 600 participants who have been diagnosed with a primary bone tumor, a soft tissue sarcoma that has invaded the bone or oligometastatic bone disease of the femur or tibia that requires surgical resection and endoprosthetic reconstruction. This article describes the overall analysis principles, including how participants will be included in each analysis, the presentation of results, adjustments for covariates, the primary and secondary outcomes, and their respective analyses. Additionally, we will present the planned sensitivity and sub-group analyses. DISCUSSION: Our prior work has demonstrated (1) high rates of SSI after the treatment of lower extremity tumors by surgical excision and endoprosthetic reconstruction, (2) highly varied opinion and practice among orthopedic oncologists with respect to prophylactic antibiotic regimens, (3) an absence of applicable RCT evidence, (4) extensive support from international investigators to participate in a RCT, and (5) the feasibility of conducting a definitive RCT to evaluate a 5-day regimen of post-operative antibiotics in comparison with a 1-day regimen.

trial registrationClinicalTrials.gov NCT01479283 . Registered on 24 November 2011.

Indexed as

Anti-Bacterial AgentsBone NeoplasmsHumansLimb SalvageSurgical Wound InfectionAnti-Bacterial AgentsAntibioticsBone sarcomaOrthopedic oncologyRandomized controlled trialStatistical analysis plan

Identifiers

PMID33752752
PMCPMC7983267
OpenAlexW3138923170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.